Minecoside promotes apoptotic progression through STAT3 inactivation in breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is a leading cause of cancer-related mortality in women globally.
• Constitutive activation of Signal Transducer and Activator of Transcription 3 (STAT3) is implicated in various malignancies, including breast cancer.
• Targeting STAT3 signaling presents a promising therapeutic strategy for breast cancer treatment.

Purpose of the Study:

• To investigate the potential antitumor effects of minecoside (MIN), a compound from *Veronica peregrina L.*, on MDA-MB-231 breast cancer cells.
• To determine if MIN inhibits the STAT3 signaling pathway.
• To explore the mechanisms underlying MIN's potential anticancer activity.

Main Methods:

• Treatment of MDA-MB-231 cells with varying concentrations and durations of MIN.
• Assessment of STAT3 activation, nuclear translocation, and DNA binding.
• Analysis of STAT3-mediated downstream protein expression (Bcl-xL, Bcl-2, CXCR4, VEGF, cyclin D1).
• Evaluation of MIN's effect on caspase-dependent apoptosis.

Main Results:

• MIN inhibited STAT3 activation in a dose- and time-dependent manner.
• MIN blocked STAT3 nuclear translocation and suppressed STAT3-DNA binding.
• MIN downregulated key STAT3-regulated proteins involved in cell survival and proliferation.
• MIN induced caspase-dependent apoptosis in MDA-MB-231 cells.

Conclusions:

• Minecoside exhibits anticancer activity against breast cancer cells by inhibiting the STAT3 signaling pathway.
• MIN effectively suppresses STAT3 activation, nuclear translocation, and downstream target gene expression.
• MIN promotes apoptosis, suggesting its potential as a novel therapeutic agent for breast cancer.
• Further in vivo studies are warranted to evaluate MIN's efficacy as an anticancer drug.